Related Experiment Video

Updated: Jul 5, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.7K

Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

Khine S Shan1, Shivani Dalal1, Nyein Nyein Thaw Dar1

  • 1Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA.

International Journal of Molecular Sciences
|January 23, 2024
PubMed

Insights

Fibroblast growth factor receptor (FGFR) alterations drive tumor development. This review covers FGFR-targeting agents, their clinical efficacy, and future directions for overcoming resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Fibroblast growth factor receptors (FGFRs) are key regulators of cell growth and survival.
  • FGFR alterations (amplifications, fusions, mutations) activate downstream signaling, promoting tumor development.
  • FGFRs are implicated in cancers like cholangiocarcinoma and urothelial carcinoma.

Purpose of the Study:

  • To review clinical experiences with FGFR-targeting agents.
  • To summarize current developments in FGFR-targeted therapies.
  • To discuss future strategies for FGFR-targeted treatment.

Main Methods:

  • Literature review of clinical trials and preclinical studies.
  • Analysis of data on FGFR inhibitors, ligand traps, antibodies, and antibody-drug conjugates.
  • Synthesis of information on efficacy, toxicity, and resistance mechanisms.

Main Results:

  • Four FGFR inhibitors are FDA-approved for specific cancers.
  • Various agents targeting the FGFR pathway are under development.
  • Current agents show variable responses, toxicities, and acquired resistance.

Conclusions:

  • Targeting FGFR alterations is a validated therapeutic strategy.
  • Further research is needed to optimize FGFR-targeted therapies.
  • Overcoming resistance and improving response rates are critical future directions.
Keywords:
FGFFGFRfibroblast growth factorfibroblast growth factor receptorgenomic profilingpersonalized medicinetargeted therapy

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.7K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K